Long-term outcomes of antiviral therapies for chronic hepatitis B

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective study recruits patients with chronic hepatitis B who are undergoing antiviral treatment. Participants will be allocated to either a peginterferon alpha-based regimen or nucleos(t)ide therapy based on their doctor's decision. The study aims to compare long-term outcomes, such as the incidence of hepatocellular carcinoma and decompensated cirrhosis, over a follow-up period of five years. Additionally, it will evaluate serological response rates and the predictive value of HBV-related laboratory tests throughout the treatment course.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male and female patients with age ≥18; subjects who are over 70 years of age must be in generally stable health conditions.
* There should be evidences that HBsAg has been positive for more than 6 months or HBV-related histological changes.
* Planned or currently receiving potent low-resistance NAs \[entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or tenofovir amibufenamide (TMF)\], or planned to receive PegIFNα-2b, either treated or treatment-naïve.
* Agree to participate in the study and sign the patient informed consent form.

Exclusion Criteria:

* Hepatocellular carcinoma (diagnosed or planned for treatment) or liver failure at baseline
* Concurrently participating in other interventional clinical trials.
* Any other conditions deemed unsuitable by investigators or preventing compliance with study requirements.

Where it's running

• Huashan Hospital
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Wenhong Zhang, MD — Huashan Hospital
• Study coordinator: Wenhong Zhang, Professor
• Email: zhangwenhong@fudan.edu.cn
• Phone: 13801844344

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of functional cure on patient-reported outcomes in chronic hepatitis B

  This study tests whether people with chronic hepatitis B who achieve a functional cure have better patient-reported outcomes compared to those not cured, relapse, or healthy controls.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou · NCT07855029

• Sequential combination therapy for functional cure of chronic hepatitis B

  This trial tests a new two-drug approach to see if adding immunotherapy to ongoing HBV treatment can lead to loss of hepatitis B surface antigen in adults with chronic hepatitis B.

  Recruiting Phase 2 The Second Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT07852091

• Combination therapy for functional cure in chronic hepatitis B

  This phase 2 trial tests whether a sequence of anti-PD-1/PD-L1 antibodies with pegylated interferon and nucleos(t)ide analogues can achieve functional cure (HBsAg loss) in adults with chronic hepatitis B.

  Recruiting Phase 2 The Second Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT07845058

• GST-HG131/GST-HG141 tablets vs placebo in chronic hepatitis B

  A phase IIa trial tests GST-HG131 and GST-HG141 tablets against placebo to see if they are safe and help people with chronic hepatitis B.

  Recruiting Phase 2 Fujian Akeylink Biotechnology Co., Ltd. · Beijing · NCT07709520

• AHB-137 injection in people with chronic hepatitis B

  This study tests AHB-137 vs placebo in adults with chronic hepatitis B who have not yet received antiviral treatment.

  Recruiting at 34 sites Phase 2 Ausper Biopharma Co., Ltd. · Beijing, Beijing Municipality and 33 other locations · NCT07635186

• AHB-137 injection pharmacokinetics and safety in people with mild to moderate liver dysfunction and normal liver function

  This study tests how AHB-137 behaves in the body and its safety in adults with chronic hepatitis B who have mild to moderate liver problems or normal liver function.

  Recruiting Phase 1 Ausper Biopharma Co., Ltd. · Chongqing, Chongqing Municipality and 4 other locations · NCT07600788

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.